August 31, 2017 / 8:54 PM / in 4 months

BRIEF-Macrogenics announces termination of duvortuxizumab collaboration

Aug 31 (Reuters) - Macrogenics Inc:

* Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen

* Macrogenics Inc - ‍enrollment of phase 1 dose-escalation study of this molecule is being discontinued​

* Macrogenics Inc - ‍Janssen has indicated that it anticipates initiating a first-in-human study with molecule in 2018​

* Macrogenics Inc - ‍Janssen reaffirmed its commitment to MGD015, also known as JNJ-9383, a second dart molecule licensed from Macrogenics​

* Macrogenics Inc - ‍Janssen is terminating collaboration and license agreement with Macrogenics relating to duvortuxizumab, a CD19 X CD3 dart molecule​

* Macrogenics Inc - ‍unlikely that co will continue development of duvortuxizumab, a CD19 X CD3 dart molecule “at this time​” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below